Determination of Regulatory Review Period for Purposes of Patent Extension; Kerendia

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for Kerendia, a human drug product, and is publishing this notice as required by law. FDA made the determination due to a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.